sion. Myocardial oxygen extraction at rest and during PT was not affected by the increase in arterial FFA. Seven patients asymptomatic during PT1 did not develop ischemic manifestations during PT2. In eight patients with angina during both PTs, increased arterial FFA concentration did not modify the severity of anginal pain, the amount of ST-segment depression and the myocardial balance of lactate or inorganic phosphate. Elevation of arterial FFA by heparin neither increased myocardial oxygen extraction at rest or during pacing nor accentuated ischemic manifestations during PT. it might be expected that pharmacological agents such as heparin or catecholamines, which increase arterial FFA, would prove hazardous in patients with ischemic heart disease. The present study was undertaken to determine whether a heparin induced elevation of arterial FFA increases myocardial oxygen extraction and ischemic manifestations at rest and during a standardized atrial pacing test in patients with angiographically documented coronary artery disease.
Patients and Methods
Fourteen males and one female, aged between 35 and 56 years, hospitalized because of chest pain for coronary arteriographic studies, agreed to participate in this investigation. No patient had congenital, primary myocardial or valvular heart disease, congestive heart failure, unstable angina or recent myocardial infarction. None had diabetes mellitus or was taking digitalis. Twelve patients had angina pectoris and eight had suffered a well documented myocardial infarction. Four patients had type IV hyperlipidemia and six type II hyperlipidemia. After a twelve hour fast, the mean plasma triglyceride concentration was 228 mg/100 ml (range 53 to 680) and the mean blood cholesterol concentration was 250 mg/100 ml (range 168 to 336). Coronary arteriographic studies, done immediately after the investigative procedure, were assessed by two independent observers. All patients had atherosclerotic narrowing of at least 50% in the right, left anterior descending and/or circumflex coronary vessel. Four patients had one coronary vessel disease, three had two vessel disease and eight had three vessel disease. All antianginal drugs were discontinued at least 48 hours before the procedure. All patients had been fasting for at least 10 hours before the procedure except for 10 mg of diazepam given orally with water one to two hours before catheterization.
From a basilic vein a number 7 After a 10 minute rest period, heart rate, aortic pressure, ECG and blood samples were obtained. Subsequently, coronary sinus pacing was begun and increased by 10 beats/min until a heart rate of at least 160 beats/min was reached or until the patient complained of angina. At the maximal heart rate, the pacing was maintained for five minutes. During the last two minutes of pacing, hemodynamic, ECG and metabolic observations were made. After pacing had been discontinued, the patients received 3000 units of crystalline heparin intravenously as a bolus and another 3000 units in a slow infusion of 0.155 M NaCl for the remainder of the study. This was followed by a thirty minute rest period, after which identical rest and pacing measurements were repeated. In four patients, atropine sulfate, 0.4 to 0.8 mg, was given during the first pacing to correct an atrioventricular block induced by pacing. No In anesthetized dogs, increased delivery of FFA to the ischemic myocardium has been shown to have deleterious effects by accentuating the ischemic process. Elevation of FFA by infusion of intralipid/heparin emulsion produced increased lactate release from the ischemic myocardium. The accentuated ischemia resulted from increased myocardial oxygen requirements due to an augmented ventricular size.4 On -the other hand, when the lipolysis induced during norepinephrine,' isoproterenol7 8,11 or dopamine10 infusion was inhibited by /-pyridilcarbinol or p-chlorophenoxysisolsutyrate, the mechanical performance remained unchanged but the ischemic injury, as assessed by epicardial ECG alone or in conjunction with myocardial lactate balance, decreased. The mechanisms responsible for the augmentation in myocardial oxygen extraction and ischemia due to the increased myocardial FFA uptake have not been defined. Inhibition of myocardial glycolysis'l and particularly of mitochondrial adenine nucleotide translocase19 due to increased intracellular concentration of long-chain acyl-CoA esters, have been entertained as hypotheses to explain this increased energy requirement.
In the present study, heparin-induced FFA elevation did not increase myocardial oxygen extraction in the 15 patients at rest. In the seven patients of group A, the heparinincreased arterial FFA failed to produce ischemic events during pacing. The eight patients of group B did not have earlier or more pronounced anginal pain, ECG or metabolic evidence of ischemia during pacing when FFA were elevated. The possibility that heparin by itself may prevent worsening of ischemia cannot be totally excluded.'0 Such an effect could explain the discrepancy between the present study and the findings reported in dogs. However it remains to be determined whether excessively high plasma FFA either alone or in association with other critical factors such as increased catecholamine levels, would have deleterious effects in more extensive and prolonged ischemia in humans. A preliminary report indicates that a nicotinic acid analog which reduces exercise-induced FFA elevation without affecting the pressure rate product, decreases the amount of ST-segment depression during and following exercise in patients with angina pectoris.n Similar observations have been obtained in patients with acute myocardial infarction during infusion of glucose-insulin-potassium." Further research is required to determine whether these results are caused by the changes in FFA concentration. Nevertheless, the results of the present study reveal that FFA elevated by heparin neither increased myocardial oxygen extraction at rest and during pacing nor accentuated ischemic manifestations during pacing in patients with coronary artery disease.
